A Neurologist's Warning: The Hidden Infection Behind Alzheimer's & ALS
What if some neurodegenerative diseases turn out to be infections we never recognized — and what does that mean for someone facing one today?
Why it matters
This is a hypothesis-driven conversation that requires careful interpretation. Dr. Jay Lombard, a board-certified neurologist, advances a hypothesis that Clostridium difficile bacterial infection is a primary trigger of neurodegenerative diseases including ALS, Alzheimer's, Parkinson's, and multiple sclerosis. The proposed mechanism: C. diff toxin (Rho kinase) damages microtubules in nerve cells, causing the protein misfolding (amyloid, tau, alpha-synuclein) that defines these diseases. Lombard further proposes that medical hyperthermia, raising body temperature to around 107°F, can disrupt bacterial spores. The question is not whether bacteria contribute to neurodegeneration (some research, including Rudy Tanzi's work at Harvard, supports that microbes do reach the brain). The question is whether C. diff specifically is THE primary trigger and whether hyperthermia is a reasonable treatment. Mainstream neurology consensus holds that Alzheimer's and ALS are driven by protein-misfolding pathology with multiple contributors (genetics, age, oxidative stress, environmental exposures); bacterial trigger hypotheses are part of an emerging research direction but are not the established cause model. Hyperthermia for ALS has no published clinical trials. Importantly, one element of this conversation, TUDCA (tauroursodeoxycholic acid), has genuine peer-reviewed neuroprotection evidence; it is part of AMX0035 (Relyvrio), which had a complicated FDA approval and withdrawal history for ALS. The episode is most useful as exposure to a hypothesis under investigation, not as a treatment guide. ALS is currently considered a progressive and life-limiting disease with limited time to act; do not delay or replace standard medical care based on this content. For someone facing a diagnosis, the key question is not whether to explore new hypotheses, but how to do so without compromising proven care.
What stands out
- The bacterial-trigger hypothesis for neurodegenerative disease is hypothesis-grade, not consensus — act accordingly
- TUDCA has real research support but the AMX0035 (Relyvrio) FDA approval and subsequent withdrawal is the cautionary tale this conversation does not fully tell
- Medical hyperthermia for ALS is not a proven treatment regardless of how it is framed; medical-tourism risk for ALS patients is real
One key action from this episode
If you or someone you love faces a neurodegenerative diagnosis, do NOT delay or replace standard medical care based on this episode. Discuss any complementary interventions with the treating neurologist before acting on them.
What to do
Actions discussed in this episode. This is what one expert recommends — the full topic compares and ranks across experts.
- If facing a neurodegenerative disease diagnosis, work with a credentialed neurologist on standard care first. Do NOT delay treatment to pursue contested hypotheses.
- If TUDCA is of interest, discuss with your treating neurologist before self-administering. The AMX0035 (Relyvrio) FDA approval and subsequent withdrawal complicates the picture this episode presents.
- If you have antibiotic exposure history, recurring gut symptoms, or family history of neurodegenerative disease, ask your doctor whether mainstream gut-microbiome and Parkinson's-risk testing is appropriate — not as a treatment, but as informed-prevention discussion.
Full context, impact ratings, and timing — available in related topics
Questions to take to your doctor
- If I have a neurodegenerative diagnosis (ALS, Alzheimer's, Parkinson's, MS), what does standard care look like for my specific stage, and what is the realistic timeline?
- Am I a candidate for any of the recently FDA-approved Alzheimer's anti-amyloid antibodies (lecanemab, donanemab), and what is the current evidence on benefit and risk?
- You may have heard about TUDCA and AMX0035 (Relyvrio) for ALS — given the FDA approval and subsequent withdrawal, what is the current clinical position on TUDCA in your practice?
- If I want to consider complementary interventions (probiotics, dietary changes, ketogenic approaches), what would you suggest is reasonable to add and what would you advise against?
- If I have a neurodegenerative-disease history of antibiotic exposure or chronic gut symptoms, are there any tests or evaluations relevant to my workup beyond standard?
- What are the warning signs of medical-tourism treatment scams, and how do I evaluate any complementary clinic claim safely?
Full doctor prep with ranked questions available in the full topic page
Context
Helps explain why microbiome-driven hypotheses for neurodegenerative disease are emerging in research, what TUDCA bile acid evidence shows, and where Lombard's specific bacterial-cause framework departs from mainstream neurology consensus.
Current evidence does not establish that C. difficile causes ALS, Alzheimer's, Parkinson's, or MS; this is a hypothesis. There are no published trials of hyperthermia for neurodegenerative disease (cancer hyperthermia research is a separate context). Lombard's clinical observations have not been peer-reviewed. The TUDCA discussion is the strongest research-supported element, but AMX0035 (Relyvrio) was FDA-approved for ALS in 2022 then withdrawn after a Phase 3 trial failed to confirm benefit; the clinical picture is more uncertain than the episode suggests. Critical safety boundary: ALS is currently considered progressive and life-limiting with limited time to act. Do not delay or replace standard medical care based on this episode. Bring any complementary intervention you are considering to your treating neurologist.
Where people go wrong
- Pursuing hyperthermia clinics in Mexico or Europe based on this episode without first discussing with your treating neurologist.There are no published trials of hyperthermia for ALS. Medical-tourism scams targeting ALS patients are widespread because the disease is progressive and life-limiting and patients are vulnerable. Standard care (riluzole, edaravone, multidisciplinary team) has documented modest benefit and access matters; do not delay or replace standard care.
- Self-administering high-dose TUDCA based on this episode's optimistic framing without knowing the AMX0035 (Relyvrio) approval and withdrawal history.AMX0035 (TUDCA + sodium phenylbutyrate) was FDA-approved for ALS in 2022, then withdrawn in 2024 after the Phase 3 trial failed to confirm clinical benefit. The episode's optimistic TUDCA framing is incomplete. TUDCA may still have a role in research and is being studied, but the clinical picture is more uncertain than presented. Discuss with a neurologist before acting.
What to expect over time
- On diagnosis: standard care firstEngage with a credentialed neurologist immediately. Establish standard care (for ALS: riluzole, edaravone, multidisciplinary team; for Alzheimer's: consider anti-amyloid antibodies for early disease, symptomatic management; for Parkinson's: dopaminergic medications, exercise, environmental modification). Do not delay standard care to pursue contested treatments.
- Considering complementary interventions: with neurologistIf you want to discuss complementary interventions (probiotics, dietary changes, fermented foods, TUDCA, ketogenic approaches), bring this episode and any specific products to your treating neurologist for review. Use evidence-based ones (vigorous exercise, structured diet) as foundation; treat speculative ones with caution.
- Long-term: track research, avoid medical tourismFollow ongoing research on microbiome-neurodegeneration, TUDCA-related compounds, and emerging cause hypotheses. Do not pursue medical-tourism hyperthermia clinics based on this content. Recognize that translating mechanistic and clinical-observation claims into actionable treatments takes years of trials and that AMX0035 history is a recent example of how that translation can fail.